EPC 2019 Updates in Pulmonary Disease

September 12, 2019 to September 15, 2019

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists, pulmonologists and allied healthcare professionals in the field of allergy, asthma and immunology.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the cellular and cytokine mechanisms that occur with Th1 driven inflammation and the diseases associated with this form of adaptive immunity, highlighting sarcoidiosis.
  • Outline how to make proper choices for the patient with uncontrolled asthma by identifying asthma phenotypes and using biomarkers to choose biologic therapy that addresses the underlying asthma endotype.
  • Discuss how to control the over-utilization of tests, treatments, and procedures in hospitalized patients in ICU settings and how to efficiently oxygenate and monitor unstable patients outside the ICU in anticipation of clinical deterioration
  • Outline the approach to weaning from mechanical ventilation and how to control spontaneous patient efforts that may be deleterious
  • Describe the clinical consequences of being at high altitude and how to prevent or treat them.
  • Explain the clinical presentations, treatments and outcomes of interstitial lung diseases including IPF and NSIP.
  • Discuss the clinical presentations, testing and radiographic assessment of the various forms of pulmonary vasculitis and how to approach treatment of these diseases
  • Explain how “real life studies” can augment results of randomized control trials.
  • Outline the recent advances the radiographic assessment of airway disease.
  • Apply current evidence-based practices to escalate and de-escalate therapy for COPD including how to use eosinophil counts and measures of atopy to help with these decisions.
  • Discuss how “GOLD 0” patients can be identified and why it is important to do so.
Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved, and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Sidney Braman, MD – Planner, Moderator, Speaker
Consultant – AstraZeneca, Circassia
Speaker – Genentech

Mario Castro, MD – Speaker
Consultant – Novartis, Sanofi, Genentech, Theravance, Vida, Teva,
Speaker –AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, Genentech, Teva
Independent Contractor –Sanofi, AstraZeneca, Chiesi, Novartis, GlaxoSmithKline
Author - Elsevier

William Corrao, MD – Moderator, Speaker
Speaker – GlaxoSmithKline

Mark Judson, MD – Speaker
Independent Contractor – Novartis, aTyr, Mallinckrodt

James Lamberti, MD – Speaker
Speaker – Janssen, Portola, Sunovion, Boehringer Ingelheim
Advisory Board – GlaxoSmithKline, Phillips

Neil MacIntyre, MD - Speaker
Consultant – Breathe Technology, Ventec

Barry Make, MD – Speaker
Consultant – AstraZeneca, GlaxoSmithKline, Circassia, Spiration, Royalty Walters Knue, UpToDate, Boehringer Ingelheim
Speaker - Sunovion
Advisory Board – Verona

Richard Martin, MD – Speaker
Consultant – Globe Life Sciences, Merck, AstraZeneca

Maria Padilla, MD – Speaker
Consultant – Boehringer Ingelheim
Speaker – Genentech

Rey Panettieri Jr., MD – Planner, Moderator, Speaker
Speaker – AstraZeneca, MedImmune, Avillion, Boehringer Ingelheim, Sanofi, Genentech
Consultant - AstraZeneca, MedImmune, Equillium, RIFM, Theravance, Avillion, Boehringer Ingelheim
Independent Contractor – AstraZeneca, MedImmune, RIFM, Equillium, Genentech, Teva,  Theratrophix, OncoArendi,

Mary Salvatore, MD – Speaker
Speaker – Genentech, Boehringer Ingelheim
Consultant – Genentech, Boehringer Ingelheim

Russell Settipane, MD – Planner, Moderator, Speaker, Reviewer
Speaker – ALK, Genentech, Pharming, Regeneron, Sanofi, Shire, Sunovion, Teva
Advisory Board – ALK, AstraZeneca, Genentech, Regeneron, Sanofi, Teva, Pharming,
Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Teva, Syneos Health

Robert Wise, MD – Speaker
Consultant – AstraZeneca, Boehringer Ingelheim, Contrafect, Pulmonx, Roche, GlaxoSmithKline, Sunovion, Merck, Mylan, Theravance, Verona, AbbVie, Propeller Health, Novartis

The following have no relevant financial relationships to disclose:

Marilyn Glassberg, MD – Speaker
Lawrence Mohr, MD – Speaker
Curt Sessler, MD – Speaker
Ginny Loiselle – Meeting Coordinator

 

Course summary
Available credit: 
  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance
Course opens: 
09/12/2019
Course expires: 
09/15/2021
Event starts: 
09/12/2019 - 4:25pm
Event ends: 
09/15/2019 - 9:30am
Cost:
$0.00
Rating: 
0
The Breakers
One South County Road
Palm Beach, FL
United States

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance

Accreditation Period

Course opens: 
09/12/2019
Course expires: 
09/15/2021

Price

Cost:
$0.00
Please login or create an account to take this course.